Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $2.7 million.

  • Foghorn Therapeutics' Share-based Compensation fell 9.44% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year decrease of 14.61%. This contributed to the annual value of $11.9 million for FY2024, which is 26.52% down from last year.
  • As of Q3 2025, Foghorn Therapeutics' Share-based Compensation stood at $2.7 million, which was down 0.00% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Share-based Compensation peaked at $4.6 million during Q1 2023, and registered a low of $1.9 million during Q1 2021.
  • In the last 3 years, Foghorn Therapeutics' Share-based Compensation had a median value of $3.1 million in 2023 and averaged $3.3 million.
  • In the last 5 years, Foghorn Therapeutics' Share-based Compensation surged by 317.59% in 2021 and then fell by 29.48% in 2024.
  • Foghorn Therapeutics' Share-based Compensation (Quarterly) stood at $2.1 million in 2021, then skyrocketed by 81.43% to $3.8 million in 2022, then fell by 19.31% to $3.1 million in 2023, then declined by 18.62% to $2.5 million in 2024, then dropped by 9.44% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.7 million for Q2 2025, and $2.7 million during Q1 2025.